12:00 AM
Jan 16, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Adcetris brentuximab vedotin regulatory update

FDA and Seattle Genetics said the label of cancer drug Adcetris brentuximab was updated to include a new boxed warning about the risk of JC virus infection resulting in progressive multifocal leukoencephalopathy (PML) and death. FDA said it received reports of 2 additional cases of...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >